506 related articles for article (PubMed ID: 25617724)
1. Lipid prodrug nanocarriers in cancer therapy.
Mura S; Bui DT; Couvreur P; Nicolas J
J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
3. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
5. A micelle-like structure of poloxamer-methotrexate conjugates as nanocarrier for methotrexate delivery.
Ren J; Fang Z; Yao L; Dahmani FZ; Yin L; Zhou J; Yao J
Int J Pharm; 2015 Jun; 487(1-2):177-86. PubMed ID: 25865570
[TBL] [Abstract][Full Text] [Related]
6. Core-shell structured gel-nanocarriers for sustained drug release and enhanced antitumor effect.
He W; Lv Y; Zhao Y; Xu C; Jin Z; Qin C; Yin L
Int J Pharm; 2015 Apr; 484(1-2):163-71. PubMed ID: 25724136
[TBL] [Abstract][Full Text] [Related]
7. Advanced drug and gene delivery systems based on functional biodegradable polycarbonates and copolymers.
Chen W; Meng F; Cheng R; Deng C; Feijen J; Zhong Z
J Control Release; 2014 Sep; 190():398-414. PubMed ID: 24858708
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment.
Voss K; Falke K; Bernsdorf A; Grabow N; Kastner C; Sternberg K; Minrath I; Eickner T; Wree A; Schmitz KP; Guthoff R; Witt M; Hovakimyan M
J Control Release; 2015 Sep; 214():1-11. PubMed ID: 26160303
[TBL] [Abstract][Full Text] [Related]
9. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
11. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
Andresen TL; Jensen SS; Jørgensen K
Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
[TBL] [Abstract][Full Text] [Related]
12. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.
Alferiev IS; Iyer R; Croucher JL; Adamo RF; Zhang K; Mangino JL; Kolla V; Fishbein I; Brodeur GM; Levy RJ; Chorny M
Biomaterials; 2015 May; 51():22-29. PubMed ID: 25770994
[TBL] [Abstract][Full Text] [Related]
14. Prodrug strategies in anticancer chemotherapy.
Kratz F; Müller IA; Ryppa C; Warnecke A
ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
[TBL] [Abstract][Full Text] [Related]
15. Advances in oral delivery of anti-cancer prodrugs.
Jain AK; Jain S
Expert Opin Drug Deliv; 2016 Dec; 13(12):1759-1775. PubMed ID: 27292717
[TBL] [Abstract][Full Text] [Related]
16. Nanocarriers for anticancer drugs--new trends in nanomedicine.
Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
[TBL] [Abstract][Full Text] [Related]
17. Amphiphilic polyelectrolyte/prodrug nanoparticles constructed by synergetic electrostatic and hydrophobic interactions with cooperative pH-sensitivity for controlled doxorubicin delivery.
Huang P; Wang W; Zhou J; Zhao F; Zhang Y; Liu J; Liu J; Dong A; Kong D; Zhang J
ACS Appl Mater Interfaces; 2015 Mar; 7(11):6340-50. PubMed ID: 25746122
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.
Fouladi F; Steffen KJ; Mallik S
Bioconjug Chem; 2017 Apr; 28(4):857-868. PubMed ID: 28201868
[TBL] [Abstract][Full Text] [Related]
19. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection.
Wang JJ; Liu KS; Sung KC; Tsai CY; Fang JY
Eur J Pharm Sci; 2009 Sep; 38(2):138-46. PubMed ID: 19591929
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Arouri A; Mouritsen OG
Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
